1169846-35-8

Usage

Uses

Used in Pharmaceutical Research and Development:
(2S,4R)-4-((7-chloro-4-methoxyisoquinolin-1-yl)oxy)-N-((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)pyrrolidine-2-carboxamide hydrochloride is utilized as a compound of interest in pharmaceutical research and development due to its unique structural features. The presence of various functional groups and the potential for specific biological activity make it a promising candidate for the development of new drugs targeting a range of therapeutic areas.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, (2S,4R)-4-((7-chloro-4-methoxyisoquinolin-1-yl)oxy)-N-((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)pyrrolidine-2-carboxamide hydrochloride serves as a valuable starting point for the design and synthesis of novel therapeutic agents. Its complex structure allows for systematic modifications to explore structure-activity relationships and optimize pharmacological properties such as potency, selectivity, and pharmacokinetics.
Used in Drug Discovery:
(2S,4R)-4-((7-chloro-4-methoxyisoquinolin-1-yl)oxy)-N-((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)pyrrolidine-2-carboxamide hydrochloride is employed in drug discovery processes to identify new lead compounds or to improve existing drug candidates. Its unique structural elements can be leveraged to target specific biological pathways or receptors, potentially leading to the development of innovative treatments for various diseases.

Upstream product

• 630423-36-8 1,7-dichloro-4-methoxyisoquinoline 
• 1028252-14-3 1,7-dichloroisoquinolin-4-ol 
• 953421-74-4 4-bromo-1,7-dichloroisoquinoline 
• 1028252-13-2 4-bromo-7-chloroisoquinolin-1-ol 
• 24188-74-7 7-chloroisoquinolin-1-ol 
• 1615-02-7 p-chlorocinnamic acid 
• 1028252-15-4 (2S,4R)-1-(tert-butoxycarbonyl)-4-((7-chloro-4-methoxyisoquinolin-1-yl)oxy)pyrrolidine-2-carboxylic acid 
• 1028252-17-6 (2S,4R)-tert-butyl 4-((7-chloro-4-methoxyisoquinolin-1-yl)oxy)-2-(((1R,2S)-1-((cyclopropylsulfonyl)-carbamoyl)-2-vinylcyclopropyl)carbamoyl)pyrrolidine-1-carboxylate 

Downstream Products

• 630420-16-5 tert-butyl ((S)-1-((2S,4R)-4-((7-chloro-4-methoxyisoquinolin-1-yl)oxy)-2-(((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)carbamate 

Relevant academic research and scientific papers

The discovery of asunaprevir (BMS-650032), an orally efficacious NS3 protease inhibitor for the treatment of hepatitis C virus infection

The discovery of asunaprevir (BMS-650032, 24) is described. This tripeptidic acylsulfonamide inhibitor of the NS3/4A enzyme is currently in phase III clinical trials for the treatment of hepatitis C virus infection. The discovery of 24 was enabled by employing an isolated rabbit heart model to screen for the cardiovascular (CV) liabilities (changes to HR and SNRT) that were responsible for the discontinuation of an earlier lead from this chemical series, BMS-605339 (1), from clinical trials. The structure-activity relationships (SARs) developed with respect to CV effects established that small structural changes to the P2* subsite of the molecule had a significant impact on the CV profile of a given compound. The antiviral activity, preclincial PK profile, and toxicology studies in rat and dog supported clinical development of BMS-650032 (24).

CRYSTALLINE FORMS OF N-(TERT-BUTOXYCARBONYL)-3-METHYL-L-VALYL-(4R)-4-((7-CHLORO-4-METHOXY-1-ISOQUINOLINYL)OXY)-N-((1R,2S)-1-((CYCLOPROPYLSULFONYL)CARBAMOYL)-2-VINYLCYCLOPROPYL)-L-PROLINAMIDE

The present disclosure generally relates to crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N-((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide. The present disclosure also generally relates to a pharmaceutical composition comprising one or more of the crystalline forms, as well of methods of using the crystalline forms in the treatment of Hepatitis C virus (HCV) and methods for obtaining such crystalline forms.